



PIONEERING NEW GENERATION Life-Science Products



OFER HAVIV | PRESIDENT & CEO

March 2025

FORWARD LOOKING STATEMENT

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

AGENDA

- ★ About Evogene
- ★ Value Proposition
- ★ Business Strategy
- ★ Success Stories
- ★ Summary

Annex I - Financial Overview
Annex II - Evogene Subsidiaries

DECODING BIOLOGY


OUR VISION

**PIONEER GROUNDBREAKING LIFE-
SCIENCE PRODUCTS ROOTED IN
MICROBES, SMALL MOLECULES,
AND GENOMICS**




DIVERSE LIFE-SCIENCE INDUSTRIES


MICROBES



SMALL MOLECULES



GENOMICS





THE COMPLEXITY

OF LIFE SCIENCE PRODUCT DEVELOPMENT

Low probability of success
with high cost and long
time-to market



Pharma Industry

Cost of developing a single
pharmaceutical drug*

In the 1970's
\$180M



In recent years
> \$2,000M



Ag-chemicals Industry

Years to develop a new crop
protection product**

1995

8Y

2000

9Y

2005-2008

10Y

2010-2014

11+Y

*Phillips McDougall, 2016.

**<https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa82d459>

THE RESOURCE KILLER

LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS

THE CHALLENGE


finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to **reach higher success rate for products**

> DISCOVERY

> OPTIMIZATION

> DEVELOPMENT

> REGULATION



TODAY WE
ARE ON THE
BRINK OF A

HISTORIC SINGULARITY POINT

Computational technology advancements enable the **discovery** and **optimization** of the most promising candidates, addressing multiple development challenges towards successful life-science based products.



LIFE-SCIENCE PRODUCT DEVELOPMENT





OUR

DECODING BIOLOGY

MISSION

WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING-EDGE AI TECHNOLOGIES TO **EFFECTIVELY DISCOVER AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS**

WHEN LIFE-SCIENCE MEETS DISRUPTIVE TECHNOLOGIES



ISRAEL
HQ

2002
Established

EVGN
NASDAQ
& TASE

106
Employees

33%
PhD's

55%
Woman

3

Innovative AI
Tech Engines

Chem
Pass^{AI}
Small Molecules

Micro
Boost^{AI}
Microbes

Gene
Rator^{AI}
Genetic Elements

4

Subsidiaries

lavie bio
better by nature
Ag Biologicals

casterra
Castor Cultivation

agPlenus
Ag Chemicals

BIOMICA
Microbiome-based
Therapeutics

COMMERCIAL PRODUCTS*

Bio-inoculant

Yalos
INOCULANT

Castor varieties

EVF701

EVF712

EVF716

*By Evogene's subsidiaries

COMMERCIAL & FINANCIAL PARTNERS



Investment &
Collaboration



Investment &
Collaboration



Collaboration



Collaboration



Collaboration



Investment



Collaboration



Collaboration



Collaboration



Collaboration



AGENDA

- ★ About Evogene
- ★ Value Proposition
- ★ Business Strategy
- ★ Success Stories
- ★ Summary


Annex I - Financial Overview
Annex II - Evogene Subsidiaries

OUR SOLUTION

Breakthrough AI Tech-Engines

Merging Technology & Science


With over a decade of intensive R&D, fueled by millions of dollars in investment, merging life-science with big- data and cutting-edge AI technology, Evogene offers dedicated **AI Tech-Engines**, designed to accelerate the discovery and optimization of life science products.



UTILIZING 3 DEDICATED AI TECH-ENGINES

WE DIRECT AND ACCELERATE LIFE-SCIENCE

Product Discovery & Optimization



The Result:

Promising candidates addressing multiple development challenges towards successful life-science-based products.



AI TECH- ENGINES

Direct & accelerate life-science
product discovery & optimization

Discovery



Computational selection of the most
promising candidates to initiate the
product development process.




Optimization

Computational driven solutions addressing
optimization challenges for the selected
candidates, while maintaining their ability
to address various other product attributes.

AI TECH-ENGINE DASHBOARD

(Example)



COLLABORATION with Google Cloud

Oct. 31, 2024 - Collaboration with Google Cloud to pioneer generative AI foundation model for novel small molecule design.

The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based products.

Google Cloud




POTENTIAL MARKET DIVERSITY

Structuring an **'ecosystem'** of diverse product types to be developed utilizing our **AI Tech-Engines**



Potential Markets for *MicroBoost AI* (Example)




AGENDA

- ✦ About Evogene
- ✦ Value Proposition
- ✦ **Business Strategy**
- ✦ Success Stories
- ✦ Summary


Annex I - Financial Overview
Annex II - Evogene Subsidiaries

A WORLD OF OPPORTUNITIES FOR OUR AI TECH ENGINES


MICROBES



SMALL MOLECULES




GENETIC ELEMENTS



BUSINESS STRATEGY

Capture the value of our AI tech-engines through diverse collaborative partnerships to accelerate life-science product development

Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene.



**MAXIMUM
POTENTIAL
MINIMUM
RISK**



BUSINESS MODEL

Two Main Partnership Structures

Capture the value of our AI tech-engines as product-development enablers, through:

LICENSING

A time-limited license grant for utilizing one of Evogene's tech-engines, to a related party for product development in a defined commercial field. In most cases the related party will be a subsidiary of Evogene.

COLLABORATION

Joint product development with a leading company utilizing Evogene's unique tech-engines. Typically, the partner leads later-stage development and product commercialization.



D1

Business Model

Licensing



Potential Revenue Stream

- License fees & R&D reimbursements
- Royalties from sale of end-products
- Dividends to Evogene as a shareholder*
- Significant one-time-payment upon an exit event**

Powered by



*Subject to meeting the Israeli dividend tests and criteria. May not be distributed in the near future or at all.

**As long as Evogene remains a major shareholder

02 Business Model

Collaboration



Potential Revenue Stream

- Upfront payments
- R&D fees
- Milestone payments
- Royalties from sale of end-products

Powered by



LICENSING & COLLABORATION | CURRENT STATUS



MICROBES



Therapeutic microbials

- Immuno-oncology program
- GI related disorders



Microbials for crops

- Bio-stimulants
- Bio-pesticides



SMALL MOLECULES



Pharma

- Small molecule-based drug discovery



Crop protection

- Weed Control
- Disease Control
- Insect Control



GENETIC ELEMENTS



Seed traits

- Improved seed traits using:
 - Genomic markers
 - Genome editing
 - GMO



Castor for bio-based industries

- Elite castor seed varieties



Food-tech

- Protein production in Plants for food-tech



Aquaculture

- Crustacean gene editing



Improved traits - canola



AGENDA

- ✦ About Evogene
- ✦ Value Proposition
- ✦ Business Strategy
- ✦ **Success Stories**
- ✦ Summary

Annex I - Financial Overview
Annex II - Evogene Subsidiaries

MISSION

Provide an integrated industrial-scale solution for castor cultivation, utilizing our elite seed varieties, for bio-based industries, with a focus on biofuels.

CASTOR OIL - EMERGING MARKET

Global castor oil market is expected to reach \$2.3 billion by 2032* CAGR of 5.1%



UNIQUE TECH PLATFORM FOR ELITE SEED VARIETIES

Combining deep scientific know-how, genomic and phenotypic big-data, and computational technology for elite castor variety development



INTEGRATED AG-SOLUTION

Elite varieties suitable for mechanized farming, growing protocols, mechanized harvesting and dehulling solutions



GLOBAL PARTNERSHIP

An alliance in the biofuel space with ENI – a leading global oil & gas company



COMMERCIAL PRODUCTS

Proprietary varieties with improved traits suitable for commercial scale cultivation
EVF716, EVF712, EVF701



*<https://www.thebrainyinsights.com/report/castor-oil-market-13954#:~:text=The%20global%20castor%20oil%20market,USD%202.3%20billion%20by%202032>

2024 milestones:


- In the first year of operation in Kenya, 890 hectares of castor were cultivated for seed production.
- Seed processing facility established in Kenya including dehulling, sorting, cleaning, coating and packaging
- The first shipment of approximately 120 tons of castor seeds, grown and processed in Kenya, has been completed.



Commercial advantage:

- Supply in geographic proximity to customers
- Saving time and money on shipping costs
- Supporting the local economy and agricultural practices





Develop
Breakthrough Products



Increase
probability of success



Reduce
time and cost

* Casterra's seed bank consists of ~500 WW germplasm accessions

MISSION

Improve food quality, sustainability and agricultural productivity through microbiome-based, **ag-biological products**

AG-BIOLOGICALS A RAPIDLY GROWING MARKET

The ag-biologicals market is expected to grow at a double digit CAGR over the next decade

UNIQUE AI TECH-PLATFORM AND DATA ASSETS

Tech-engine promoting discovery and development of microbial products

Powered by
 **Micro
Boost^{AI}**

BROAD & DIVERSE PIPELINE

8 programs under development; new product launch expected every 1-2 years

STRATEGIC INVESTORS & PARTNERS




COMMERCIAL PRODUCT



SOLD IN USA & CANADA**
& expanding globally




SUPERIOR PERFORMANCE
vs. alternatives



CONSISTENT PERFORMANCE



* Yalos® has regulatory approval in the US & Canada for all small grains including wheat, barley, durum, oats, soybeans, canola, and others. Data was gathered in large side-by-side field trials in the US
 ** In 2023 Yalos® was sold for wheat. 2023 trials for barley and durum look promising for potential 2024 expansion



Develop
Breakthrough Products



Increase
probability of success



Reduce
time and cost

AGENDA

- ✦ About Evogene
- ✦ Value Proposition
- ✦ Business Strategy
- ✦ Success Stories
- ✦ **Summary**

Annex I - Financial Overview
Annex II - Evogene Subsidiaries

VISION

Pioneer groundbreaking life-science products rooted in microbe, small molecule, and genomics innovations.

MISSION


We merge scientific expertise with cutting-edge AI and big data technologies to discover and optimize innovative life-science products effectively.

OFFERING

3 dedicated AI Tech-Engines that efficiently direct and **accelerate** the development of **breakthrough** life-science products.

BUSINESS STRATEGY

MAXIMUM POTENTIAL, MINIMUM RISK



EVOGENE GROUP'S PRODUCTS & PARTNERSHIPS

Bio-inoculant

Yalos[®]
INOCULANT

Castor varieties

 EVF701
 EVF712
 EVF716



evogene
DECODING BIOLOGY

THANK YOU



Annex I

FINANCIAL OVERVIEW



KEY FINANCIALS: BALANCE SHEET

Key Points:

- Consolidated cash position: ~\$15.3 million as of 31.12.2024
- No** bank debt


Thousands of US \$	31.12.2024	31.12.2023
Current Assets	21,589	34,469
Long-Term Assets	18,275	16,632
Total Assets	39,864	51,101
Current Liabilities (inc. ~\$10m convertible SAFE at Lavie Bio)	18,695	6,944
Long-Term Liabilities	6,331	15,472
Equity attributable to equity holders of the Company	(1,451)	12,053
Non-controlling interest	16,289	16,632
Total Liabilities & Shareholders Equity	39,864	51,101

KEY FINANCIALS: BALANCE SHEET

Key Points:

- Revenues - year 2024 \$8.5M vs. \$5.6M in year 2023.
- Operating loss - year 2024 \$22.2M vs. \$26.5M in year 2023
- 2024 cash usage, excluding Lavie Bio and Biomica ~\$10.4M, down from ~\$12.5M in 2023

Thousands of US \$	1-12/2024	1-12/2023
Revenues	8,511	5,640
Cost of revenues	2,683	1,692
Gross profit	5,828	3,948
Research and development, net	16,648	20,777
Sales and marketing	3,425	3,611
General and administrative	7,441	6,068
Other expenses	524	-
Total operating expenses, net	28,038	30,456
Operating loss	(22,210)	(26,508)
Financing income (expenses), net	4,204	521
Share of loss of an associate	39	-
Loss before taxes on income	(18,045)	(25,987)
Taxes on income (tax benefit)	9	(33)
Loss	(18,054)	(25,954)



Annex II

EVOGENE

SUBSIDIARIES



Castor Seed Production

CASTERRA'S MISSION:

Provide an integrated industrial-scale solution for castor cultivation, utilizing our elite seed varieties, for bio-based industries, with a focus on biofuels

2008

Established

2

Production sites
(Kenya & Brazil)

IL

HQ
R&D

>500

Core collection
germplasm

>1,000MT

Seed
production

3

Commercial
products

**CURRENT
PARTNERS**



Collaboration

Powered by



Expected Value Drivers

- Global partnership – extending the collaboration frame in the biofuel & biopolymer spaces – more territories and new global partners
- Developing castor varieties with traits that are commercially valuable for the biofuel & biopolymer industries
- First pilots for growing castor grain for oil production
- Improving castor growing agro-technics and advanced growing systems
- Improving & optimizing seed production operations in Africa & Latin America

Latest News



Ag Biologicals

LAVIE BIO'S MISSION:

Improve food quality, sustainability and agriculture productivity through microbiome based, AI-driven, ag-biological products

2019

Established

17

Employees

IL

HQ

7

Products in development

1

Commercial product

IL, US & EU

R&D

CURRENT PARTNERS



Investment & Collaboration



Investment & Collaboration



Collaboration

Powered by



Expected Value Drivers

BIO-PESTICIDES

- LAV311 - US regulatory approval for bio-fungicide candidate for fruit rots – expected in 2025
- LAV321 - submission of Lavie Bio's bio-fungicide candidate for downy mildew to the US EPA for regulatory approval – expected in 2025
- Co-development and licensing agreement for an additional bio-pesticide program with a large multinational company – expected in 2025

BIO-STIMULANTS

- Yalos® – distribution licensing agreements and sales expansion in USA & Canada. Expansion to soybeans and additional crops in 2025
- Co-development and licensing agreement for an additional bio-stimulant program with a large multinational company – expected in 2025

Latest News



Ag-Chemicals

AGPLENUS' MISSION:

Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology

2018

Established

11

Employees

IL

HQ
R&D

6

Programs under
development

3

Programs under
collaboration

2

Strategic
partners

**CURRENT
PARTNERS**



Collaboration



Collaboration

Powered by



Expected Value Drivers

Weed Control

- Corteva collaboration – Drive projects towards next milestone
- Bayer collaboration - design novel optimize molecules

Fungal Control

Enhance and expand the existing pipeline program to include:

- additional targets and corresponding hits
- optimize the existing hits

Latest News



Human Microbiome

BIOMICA'S MISSION:

Discovery and development of novel microbiome-based therapeutics for human disorders, utilizing cutting edge computational capabilities

2017

Established

17

Employees

IL

HQ
R&D

1

Leading program -
phase 1

3

Programs - clinical
/preclinical stage

\$20M

Recent financing
round

**CURRENT
PARTNERS**



Investment

Powered by



Expected Value Drivers

- Complete Phase 1 study in oncology program; obtain full results and additional supporting clinical data.
- Submit IND application to the US FDA and obtain FDA approval for the Phase 2 study.
- Obesity and Longevity programs: complete discovery & in-vitro validations; seek partners for both programs.

Latest News